Women in Clinical Trials: How Decades of Underrepresentation Shaped Modern Medicine
By Ravoke News Desk For much of modern medical history, women have been significantly underrepresented in clinical research, despite accounting for nearly half of the world’s population. While scientific advances
By Ravoke News Desk
For much of modern medical history, women have been significantly underrepresented in clinical research, despite accounting for nearly half of the world’s population. While scientific advances have transformed healthcare over the past century, many treatments currently prescribed today were originally developed and tested primarily in male participants.
Researchers and healthcare experts say that imbalance has contributed to knowledge gaps about how diseases develop in women, how medications are processed by the female body, and whether certain therapies should be prescribed or dosed differently based on biological sex.
Although participation has improved considerably over the past three decades, experts believe more work remains to ensure clinical trials accurately reflect the populations they are intended to serve.
Why Representation in Clinical Trials Matters
Clinical trials are the foundation of modern medicine. Before a new drug, vaccine, medical device, or treatment becomes available to the public, researchers rely on carefully designed clinical studies to evaluate safety, effectiveness, and potential side effects.
The quality of those studies depends heavily on who participates.
When important demographic groups are excluded or poorly represented, researchers may not fully understand how treatments affect different populations. Age, ethnicity, genetics, underlying health conditions, and biological sex can all influence how a medication performs.
Women, in particular, experience unique hormonal changes throughout life, including puberty, pregnancy, menopause, and aging. These biological differences can influence everything from immune responses to metabolism and cardiovascular health.
As precision medicine continues to evolve, scientists increasingly recognize that one-size-fits-all approaches often fail to provide the best outcomes.
A Long History of Male-Dominated Medical Research
For decades, the majority of biomedical research relied overwhelmingly on male participants.
Scientists frequently considered adult men to represent the “standard” research subject, believing that studying women introduced additional complexity because of hormonal fluctuations associated with the menstrual cycle.
This approach extended beyond human research. Animal studies also routinely favored male laboratory animals to simplify experimental design, meaning potential sex-related biological differences often went unexplored before medications reached human testing.
The consequences stretched across nearly every field of medicine, including cardiology, neurology, oncology, and pharmacology.
As a result, physicians often prescribed treatments to women using evidence gathered primarily from studies involving men.
Historical Decisions That Limited Women’s Participation
Several historical events reinforced the exclusion of women from clinical research.
One of the most influential was the thalidomide tragedy during the late 1950s and early 1960s. The medication, prescribed in several countries to relieve morning sickness during pregnancy, caused thousands of babies to be born with severe birth defects.
The disaster prompted regulators worldwide to strengthen protections surrounding clinical research involving pregnant women.
In 1977, the U.S. Food and Drug Administration issued guidance discouraging the participation of women of childbearing potential in many early-stage clinical trials. Although designed to protect unborn children from unknown risks, the policy affected a far broader group than pregnant women alone.
Women who were not pregnant—including those using contraception or otherwise unlikely to become pregnant—were also frequently excluded from research participation.
While the restrictions were intended as a safety measure, researchers now acknowledge they also contributed to decades of missing information about how medications affected women.
The Cost of Missing Data
Medical experts emphasize that excluding women from research does not eliminate risk—it simply shifts uncertainty into everyday medical practice.
Without sufficient female participation, physicians have historically had limited evidence about appropriate dosing, side effects, and long-term safety for women.
In some cases, medications have later been found to affect women differently than men because of differences in body composition, hormone levels, liver metabolism, and kidney function.
These findings have reinforced calls for clinical trials to include participants who better represent real-world patient populations.
Heart Disease: A Clear Example of the Knowledge Gap
Cardiovascular disease illustrates the consequences of historical research imbalance.
For many years, heart disease was widely viewed as primarily affecting men, leading many cardiovascular studies to recruit predominantly male participants.
Modern research has demonstrated that women often experience heart disease differently.
Symptoms can vary, risk factors may differ, and women sometimes present with less typical warning signs than men.
Because earlier studies focused largely on male patients, physicians had less evidence regarding how cardiovascular disease developed in women and whether treatments should be adjusted accordingly.
Recent decades have seen growing efforts to correct these disparities through larger, more representative clinical trials.
Progress Since the 1990s
The landscape of clinical research began changing during the late 1980s and early 1990s.
The U.S. National Institutes of Health introduced policies encouraging greater participation by women, while federal legislation in 1993 formally strengthened requirements for including women in federally funded clinical studies.
These changes coincided with increased attention to women’s health research and the launch of large-scale initiatives examining diseases that disproportionately affect female patients.
Since then, participation has steadily increased across many therapeutic areas.
However, researchers say improvements have not eliminated disparities.
Analyses published over the past several years continue to show that women remain underrepresented in numerous clinical studies, particularly during early phases of drug development.
Some preclinical laboratory research also continues to rely heavily on male animal models, limiting opportunities to identify sex-specific biological differences before human testing begins.
Biological Differences Can Influence Drug Response
Modern pharmacology recognizes that biological sex affects how medicines move through the body.
Processes such as absorption, distribution, metabolism, and elimination can vary between women and men because of differences in body fat composition, enzyme activity, hormone levels, and organ function.
These variations mean that identical doses do not always produce identical effects.
Researchers increasingly believe that understanding these biological differences is essential for improving medication safety while supporting the broader shift toward personalized medicine.
Rather than assuming treatments work equally well for everyone, scientists now seek evidence showing how therapies perform across diverse patient populations, helping physicians make more informed treatment decisions.
Women in Clinical Trials: How Regulators and Researchers Are Building a More Inclusive Future
When Medication Effects Differ Between Women and Men
The importance of including women in clinical research becomes especially clear when examining cases where medications have produced different outcomes based on biological sex.
One well-known example involved a prescription sleep medication that was approved in the early 1990s. Years after approval, researchers identified that women who took the medication were more likely than men to experience next-day impairment, including increased risks associated with driving.
Further investigation revealed that women retained higher levels of the active ingredient in their bloodstream compared with men who received the same dose. The discovery led regulators to recommend a lower starting dose for women.
The case became an important example of why clinical trials must examine differences between male and female participants before treatments become widely available.
Researchers have since found that sex-based differences can influence many aspects of medicine, including how quickly drugs are broken down, how they interact with enzymes, and how strongly patients respond to certain therapies.
The Science Behind Sex-Specific Treatment Responses
Biological sex can influence the way the human body processes medications.
For example, differences in body composition can affect how compounds are distributed throughout the body. On average, women and men differ in the percentage of body fat and water composition, which can influence how certain substances are absorbed and stored.
Hormones can also play an important role. Estrogen, testosterone, and other biological signals affect immune function, metabolism, and organ activity, potentially changing how diseases develop and how treatments work.
Researchers say these differences do not mean every treatment requires separate approaches for women and men. Instead, they highlight the importance of collecting enough data from both groups so medical decisions are based on evidence rather than assumptions.
As healthcare moves toward personalized medicine, understanding these variations has become increasingly important.
Why Women Still Face Barriers to Clinical Trial Participation
Although enrollment of women in clinical studies has improved, researchers say participation challenges remain.
Underrepresentation is not caused by a single issue. Instead, experts point to several barriers that can influence whether women are able or willing to participate.
Some challenges include:
Trial Design Issues
Clinical studies that do not establish clear diversity goals during planning may struggle to recruit participants who reflect the broader patient population.
Researchers increasingly recommend building representation strategies into trials from the beginning rather than attempting to correct enrollment gaps later.
Practical Challenges
Many potential participants face logistical barriers, including transportation difficulties, scheduling conflicts, work responsibilities, and childcare needs.
These challenges can disproportionately affect women, particularly those balancing caregiving responsibilities with employment or family obligations.
Communication and Trust
A person’s decision to participate in research can also be influenced by how information is presented.
Clear communication, culturally appropriate materials, and strong relationships between researchers and communities can improve awareness and trust.
Clinical trial consent documents and educational materials must also be understandable and accessible so participants can make informed decisions.
Social and Cultural Factors
Personal beliefs, previous experiences with healthcare systems, and community attitudes can influence willingness to participate.
Researchers increasingly recognize that improving diversity requires engagement with communities before trials begin, not only during recruitment.
New Regulations Aim to Improve Diversity in Research
Health regulators around the world have introduced new policies designed to make clinical research more representative.
In the United States, the Food and Drug Administration has increased its focus on diversity in clinical trials through policies encouraging sponsors to create formal plans for improving enrollment among historically underrepresented groups.
The Food and Drug Omnibus Reform Act of 2022 introduced requirements for Diversity Action Plans, encouraging clinical trial sponsors to outline strategies for increasing participation among groups that have traditionally been overlooked.
These plans consider more than sex alone. They also address factors such as race, ethnicity, age, and other demographic characteristics that influence healthcare outcomes.
The FDA has also issued additional guidance emphasizing that clinical studies should better reflect the populations likely to receive approved treatments.
Global Efforts to Create More Representative Research
Efforts to improve diversity are not limited to the United States.
Regulatory organizations in other countries have also emphasized the importance of inclusive clinical trials.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency and Health Research Authority have supported approaches that encourage researchers to consider diversity during study planning and recruitment.
These initiatives aim to ensure that medical discoveries benefit the widest possible range of patients.
Researchers say inclusive trials are not only an issue of fairness—they are also a scientific necessity. A treatment that works well in one population may have different effects in another, making broad representation essential for accurate medical knowledge.
The Future of Women’s Health Research
The medical research community has made significant progress since the policies of the 1990s increased women’s participation in clinical studies. However, experts say continued action is needed to close remaining gaps.
Future clinical trials are expected to place greater emphasis on analyzing results by sex, rather than simply reporting overall outcomes.
Researchers are also calling for more women to be included in early-stage drug development, where important safety and effectiveness decisions are first established.
Advances in technology, improved data analysis, and stronger regulatory requirements are helping scientists better understand differences between patient groups.
The goal is not to create separate medicine for men and women, but to develop treatments supported by evidence from the people who will ultimately use them.
A More Accurate Future for Healthcare
For decades, women were frequently treated as a population to be studied later rather than an essential part of medical research from the beginning.
That approach created lasting gaps in scientific understanding, but changes in regulation, research practices, and public awareness are reshaping the future of clinical trials.
Ensuring women are fully represented in medical studies will allow researchers to better understand diseases, improve treatment safety, and develop therapies that work effectively for all patients.
As medicine continues moving toward precision healthcare, diversity in clinical research will remain a critical part of building a healthcare system based on stronger evidence and better outcomes.
